Manifold Bio

manifold.bio →

+126%

est. 2Y upside i

HealthcareSeries A

Tissue-targeted medicines, designed in vivo.

Rank

#307

Sector

Biotechnology

Est. Liquidity

~6Y

Data Quality

Data: Medium

Manifold Bio presents a strong upside opportunity driven by its innovative AI-guided direct-to-vivo discovery platform and a significant strategic collaboration with Roche, including a $55 million upfront payment and potential for $2 billion in milestones.

Last updated: March 10, 2026

Bull (35%)+350%

Manifold Bio's AI-guided direct-to-vivo platform achieves significant clinical validation for its brain shuttle technology, leading to multiple successful programs with Roche and attracting new major pharma collaborations. This success drives an acquisition or IPO at a valuation of $2.7 billion or higher, representing a 350% upside from the current estimated valuation.

Base (35%)+75%

The Roche collaboration progresses steadily with initial positive preclinical data, but clinical trials are lengthy and costly. Manifold Bio secures additional, smaller partnerships and continues to build its internal pipeline, leading to an eventual acquisition or later-stage funding round at a valuation of approximately $1.05 billion, a 75% upside.

Bear (30%)-75%

Manifold Bio faces unforeseen challenges in translating its platform to clinical success, or the Roche collaboration encounters significant setbacks. Increased competition in the AI drug discovery space or difficulties in securing further capital lead to a down round or an acquisition at a distressed valuation of $150 million, resulting in a 75% downside for common shareholders.

Est. time to liquidity~6.0 years

Preference Stack Risk

moderate

Investors hold $78 million in liquidation preferences, meaning common shareholders would see returns only after this amount is paid out in an exit.

Dilution Risk

moderate

As a Series A company in a capital-intensive sector, multiple future funding rounds are anticipated, which will likely lead to further dilution of employee equity.

Secondary Liquidity

none

There is currently no active secondary market or tender offers for Manifold Bio shares.

View all 6 open roles at Manifold Bio →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Manifold Bio's data — designed to show you've done your homework.

  • 1

    “Given the $55 million upfront payment from Roche and the potential $2 billion deal, how does Manifold Bio plan to leverage this partnership to accelerate its internal pipeline development and attract further collaborations?”

  • 2

    “With an estimated annual revenue of $8.4 million and high capital intensity, what are the key milestones and financial targets the company aims to achieve in the next 18-24 months to prepare for future funding rounds or a liquidity event?”

  • 3

    “Considering the competitive landscape in AI-guided drug discovery, how does Manifold Bio's 'direct-to-vivo' platform provide a sustainable competitive advantage against larger incumbents and other well-funded startups in the long term, particularly regarding data generation and predictive modeling?”

Community

Valuation Sentiment

Our model estimates +126% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.